BRIEF-Polyrizon Expects Nasarix Introduction Aligned With Clinical Progress

Polyrizon's PL-14 Outperforms Standard Nasal Barrier in Blocking Allergens

Polyrizon Submits FDA Pre-Request for Designation for PL-16 Nasal Spray

BRIEF-Polyrizon To Explore Investment In Revenue-Generating Real Assets

Polyrizon Ltd - to Explore Investment in Revenue-Generating Real Assets

Polyrizon Ltd. to Explore Revenue-Generating Real Asset Investments While Continuing Development of Core Medical Pipeline

Polyrizon Submits Pre-Request for FDA Designation for PL-16 Viral Blocker

Polyrizon Submits Pre-Request for Designation to FDA for Pl-16 Viral Blocker Designed to Reduce the Exposure to Influenza and Cold Viruses

Polyrizon Reports Intranasal Naloxone Hydrogel Matches Marketed Product in Rapid Permeation

Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program

BRIEF-Polyrizon Completes FDA Pre-Submission Meeting For PL-14 Allergy Blocker Nasal Spray

Polyrizon Completes FDA Pre-Submission Meeting for Pl-14 Allergy Blocker Nasal Spray

Top Premarket Decliners

Crude Oil Gains Over 1%; Kroger Shares Slide After Q3 Results

Polyrizon Achieves Manufacturing Milestone for Nasal Hydrogel Barrier

BRIEF-Polyrizon Reports Positive Mucoadhesion Results For Intranasal Naloxone Hydrogel

Polyrizon Reports Positive Mucoadhesion Results for Intranasal Naloxone Hydrogel Compared to Marketed Intranasal Naloxone Product

Polyrizon Reports Superior Mucoadhesion for Intranasal Naloxone Hydrogel in Preclinical Study